SWiss Multicenter Intracoronary Stem Cells Study in Acute Myocardial Infarction (SWISS-AMI)
Acute Myocardial Infarction
About this trial
This is an interventional treatment trial for Acute Myocardial Infarction focused on measuring acute myocardial infarction, MRI, bone marrow cells, stem cells, remodeling
Eligibility Criteria
Inclusion Criteria: Visual LVEF at angiogram or echocardiography ≤45% Treatment by primary PCI within 24 hours of the onset of chest pain or initial treatment with thrombolysis within the 12 hours followed by PCI within the 24 hours of the onset of chest pain Significant regional LV wall motion dysfunction in the infarct related territory Age >18 years Exclusion Criteria: Abnormal regional wall motion outside the infarct region Known previous myocardial infarction in the same target vessel Known pre-existing left ventricular dysfunction (EF<45% prior to admission) Need for revascularization in the non infarct-related coronary within 4 months Pre-existing symptoms of heart failure or known cardiomyopathy Known active infection or chronic infection with HIV, HBV or HCV Chronic inflammatory disease Serious concomitant disease with a life expectancy of less than one year Follow up impossible (no fixed abode, etc) Contraindication for cardiac MRI (i.e. pace maker, neurostimulator, claustrophobia) Severe renal failure (creatinine >250 mmol/l) Relevant liver disease (GOT > 2x norm or spontaneous INR > 1,5) Anemia (Hb < 8.5 mg/dl), Thrombocytopenia (<100.000/µl) Pregnancy Participation at a clinical trial in the last 30 days
Sites / Locations
- Cardiology, University Hospital Berne
- Kantonsspital
- Cardiocentro Ticino
- Cardiology, university Hospital Zurich
Arms of the Study
Arm 1
Arm 2
Arm 3
No Intervention
Experimental
Experimental
Control
Early
Late